ReviewDrugs2015
Naltrexone ER/Bupropion ER: A Review in Obesity Management.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- The weight reducing effects of naltrexone-bupropion among obese psychiatric and non-psychiatric patients: a systematic review.Psychopharmacology · 2025Pooled it
- Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions.Endocrinology, diabetes & metabolism · 2026Review
- Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury.Frontiers in pharmacology · 2025Article
- Real-World Effectiveness and Tolerability of Low Dose Naltrexone to Treat Chronic Pain: A Retrospective Cohort Study of One Pain Physician's Practice.Journal of pain research · 2025Article
- Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.BMC pharmacology & toxicology · 2024Article
- Update on Pediatric Anti-obesity Medications-Current Landscape and Approach to Prescribing.Current obesity reports · 2024Review
- Insights into the Current and Possible Future Use of Opioid Antagonists in Relation to Opioid-Induced Constipation and Dysbiosis.Molecules (Basel, Switzerland) · 2023Review
- Clinical and Therapeutic Implications of Male Obesity.Journal of clinical medicine · 2023Review
- Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases.Biomedicines · 2023Review
- GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.Frontiers in endocrinology · 2023Review
- Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2022Article
- Signaling pathways in obesity: mechanisms and therapeutic interventions.Signal transduction and targeted therapy · 2022Review
- Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches.Journal of endocrinological investigation · 2021Review
- Pharmacotherapy in pediatric obesity: current evidence and landscape.Current opinion in endocrinology, diabetes, and obesity · 2021Review
- Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.Diabetes & metabolism journal · 2020Review
- Medications for the treatment of obesity in adolescents.Therapeutic advances in endocrinology and metabolism · 2020Review
- Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice.Pharmacology, biochemistry, and behavior · 2019Article
- Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys.Pharmaceutical research · 2018Article
- Orphan neuropeptides and receptors: Novel therapeutic targets.Pharmacology & therapeutics · 2018Review
- The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review.Journal of pharmaceutical policy and practice · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave(®), Mysimba(™)) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥ 30 kg/m(2) (i.e. obese) or a BMI of ≥ 27 kg/m(2) (i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. In 56-week phase III trials in these patient populations, oral naltrexone ER/bupropion ER 32/360 mg/day was significantly more effective than placebo with regard to percentage bodyweight reductions from baseline and the proportion of patients who achieved bodyweight reductions of ≥ 5 and ≥ 10%. Significantly greater improvements in several cardiometabolic risk factors were also observed with naltrexone ER/bupropion ER versus placebo, as well as greater improvements in glycated haemoglobin levels in obese or overweight adults with type 2 diabetes. Naltrexone ER/bupropion ER was generally well tolerated in phase III trials, with nausea being the most common adverse event. Thus, naltrexone ER/bupropion ER 32/360 mg/day as an adjunct to a reduced-calorie diet and increased physical activity, is an effective and well tolerated option for chronic bodyweight management in obese adults or overweight adults with at least one bodyweight-related comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.